Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 11/20 | 0.47 |
| ▸ | PPARA | Q07869 | 10/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981877 | 0.94 | FFAR1 (0.49) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3983944 | 0.94 | FFAR1 (0.49) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL27636270 | 0.94 | FFAR1 (0.49) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3987750 | 0.94 | FFAR1 (0.48) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3984825 | 0.94 | FFAR1 (0.48) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3984174 | 0.94 | FFAR1 (0.48) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3985575 | 0.93 | FFAR1 (0.47) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3979931 | 0.93 | FFAR1 (0.47) | FFAR1PPARGPPARAMAPTTP53 | |
| SCHEMBL3986596 | 0.92 | FFAR1 (0.51) | FFAR1PPARGPPARAMAPTKDR | |
| SCHEMBL3990106 | 0.91 | MAPT (0.51) | FFAR1PPARGPPARAMAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | claimed |
| CN-100447139-C | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2008-12-31 | — | — | CN | claimed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | claimed |
| CN-1816546-A | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | claimed |
| EP-1646628-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Novartis AG (CH) | 2006-04-19 | — | — | EP | claimed |
| WO-2005005421-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | claimed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| US-7538135-B2 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2009-05-26 | — | — | US | disclosed |
| CN-100447139-C | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2008-12-31 | — | — | CN | disclosed |
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2007-02-22 | — | — | US | disclosed |
| CN-1816546-A | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | NOVARTIS AG (CH) | 2006-08-09 | — | — | CN | disclosed |
| EP-1646628-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Novartis AG (CH) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005005421-A1 | BENZENESULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NOVARTIS AG (CH) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043020-A1 | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds | PPARG, PPARA, PPARD | FFAR1 19/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.